Introduction: Gene therapy have recently attracted much attention as a curative therapeutic option for inherited single gene disorders such as hemophilia. Hemophilia is a hereditary bleeding disorder caused by the deficiency of clotting activity of factor VIII (FVIII) or factor IX (FIX), and gene therapy for hemophilia using viral vector have been vigorously investigated worldwide. Toward further advancement of gene therapy for hemophilia, we have previously developed and validated the efficacy of novel two types of gene transfer technologies using a mouse model of hemophilia A. Here we investigated the efficacy and safety of the technologies in canine model. Especially, validations of technical procedures of the gene transfers for dogs wer...
Hemophilia is an inherited bleeding disorder caused by the lack of a protein necessary for blood clo...
High-capacity adenoviral (HC-Ad) vectors expressing B-domain-deleted human or canine factor VIII fro...
Preclinical testing of new therapeutic strategies in relevant animal models is an essential part of ...
We investigated the efficacy of liver-directed gene therapy using lentiviral vectors in a large anim...
Severe hemophilia A (HA) is an inherited bleeding disorder characterized by <1% of residual factor V...
A key issue in gene therapy is the immune response to the therapeutic transgene. This is especially ...
A key issue in gene therapy is the immune response to the therapeutic transgene. This is especially ...
Sleeping Beauty (SB) transposase enables somatic integration of exogenous DNA in mammalian cells, bu...
Hemophilia B is a severe X-linked bleeding diathesis caused by the absence of functional blood coagu...
Adenoviral vector-mediated gene therapy might have potential for long-term correction of the monogen...
Dogs with hemophilia A, hemophilia B, von Willebrand disease (VWD), and factor VII deficiency faithf...
Hemophilia B is a bleeding disorder caused by mutations in the factor IX gene. The disorder is X-lin...
Hemophilia A and B are hereditary coagulation defects resulting from a deficiency of factor VIII (FV...
Hemophilia A and B are X-linked monogenic disorders caused by deficiencies in coagulation factor VII...
Both haemophilia A and B are X-linked recessive disorders and therefore occur almost exclusively in ...
Hemophilia is an inherited bleeding disorder caused by the lack of a protein necessary for blood clo...
High-capacity adenoviral (HC-Ad) vectors expressing B-domain-deleted human or canine factor VIII fro...
Preclinical testing of new therapeutic strategies in relevant animal models is an essential part of ...
We investigated the efficacy of liver-directed gene therapy using lentiviral vectors in a large anim...
Severe hemophilia A (HA) is an inherited bleeding disorder characterized by <1% of residual factor V...
A key issue in gene therapy is the immune response to the therapeutic transgene. This is especially ...
A key issue in gene therapy is the immune response to the therapeutic transgene. This is especially ...
Sleeping Beauty (SB) transposase enables somatic integration of exogenous DNA in mammalian cells, bu...
Hemophilia B is a severe X-linked bleeding diathesis caused by the absence of functional blood coagu...
Adenoviral vector-mediated gene therapy might have potential for long-term correction of the monogen...
Dogs with hemophilia A, hemophilia B, von Willebrand disease (VWD), and factor VII deficiency faithf...
Hemophilia B is a bleeding disorder caused by mutations in the factor IX gene. The disorder is X-lin...
Hemophilia A and B are hereditary coagulation defects resulting from a deficiency of factor VIII (FV...
Hemophilia A and B are X-linked monogenic disorders caused by deficiencies in coagulation factor VII...
Both haemophilia A and B are X-linked recessive disorders and therefore occur almost exclusively in ...
Hemophilia is an inherited bleeding disorder caused by the lack of a protein necessary for blood clo...
High-capacity adenoviral (HC-Ad) vectors expressing B-domain-deleted human or canine factor VIII fro...
Preclinical testing of new therapeutic strategies in relevant animal models is an essential part of ...